Suvorexant as an Adjunct to Buprenorphine in Persons Who Use Fentanyl
Status:
Not yet recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
This is a 4-week, randomized-controlled trial of suvorexant vs placebo in persons with opioid
use disorder who have recent fentanyl exposure. Participants will first undergo a 5-day
residential phase wherein participants are stabilized on sublingual buprenorphine/naloxone,
followed by a 3-week outpatient phase wherein participants are maintained on sublingual
buprenorphine/naloxone and transitioned to extended-release buprenorphine).